Cargando…
Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927482/ https://www.ncbi.nlm.nih.gov/pubmed/29721387 http://dx.doi.org/10.1080/2162402X.2018.1424674 |